Intravenous Lidocaine Plus Intratracheal Dexmedetomidine on Postoperative Sore Throat

Not Applicable

Not yet recruiting

• Conditions: Dexmedetomidine; Lidocaine; Sore Throat
• Interventions: Drug: Intravenous lidocaine; Drug: Intracheal dexmedetomidine; Drug: Intravenous lidocaine combined with intracheal dexmedetomidine; Drug: Saline (NaCl 0,9 %) (placebo)

• Registration Number: NCT06952309
• Lead Sponsor: Anqing Municipal Hospital

Brief Summary

Objective: The present study was to investigate the effect of intravenous lidocaine combined with intratracheal dexmedetomidine on postoperative sore throat in patients undergoing thyroid cancer surgery.

Methods: Investigators enrolled 144 patients with American Society of Anesthesiologists (ASA) physical status I and II, aged 18-65 years, and scheduled for elective undergoing thyroid cancer surgery with general anesthesia. The participants were randomly assigned into four groups(n=36 each group): Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia. Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL). Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL). Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia.The incidence and severity of postoperative sore throat were recorded in four groups at 1 h, 2 h, 6 h, 24 h and 48 h after operation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-04
• Study First Submitted: 2025-04-20
• Study Start: 2025-04-25
• Study First Submitted QC: 2025-04-28
• Last Update Submitted: 2025-04-28
• Study First Posted: 2025-04-30
• Last Update Posted: 2025-04-30
• Primary Completion: 2025-09-15
• Study Completion: 2025-09-25

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

• Thyroid cancer surgery with ASA grades I-II
• Aged 18-65 years
• The patient's communication is normal and they have a certain learning ability

Exclusion Criteria

• Severe respiratory and circulatory system diseases
• There was bradycardia (HR < 60 beats/minute) or atrioventricular block before the operation
• Nervous system disease
• Mental and psychological disorders
• Abnormal liver and kidney functions
• Pregnant and lactating women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intravenous lidocaine	Intravenous lidocaine	Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
Intracheal dexmedetomidine	Intracheal dexmedetomidine	Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
Intravenous lidocaine combined with intracheal dexmedetomidine	Intravenous lidocaine combined with intracheal dexmedetomidine	Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
Saline	Saline (NaCl 0,9 %) (placebo)	Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia

Primary Outcome Measures

Name	Time	Method
The incidence and severity of postoperative sore throat	at 1 hour, 2 hour, 6 hour, 24 hour and 48 hour after operation